F-18-NaF Bone PET¹⁸F-sodium fluoride
High-resolution PET bone imaging of osteoblastic activity
Quick Answer
F-18-sodium fluoride is a PET bone-seeking agent that deposits into hydroxyapatite at sites of osteoblastic activity and blood flow — the same physiology as Tc-99m-diphosphonates but with the resolution, sensitivity, and quantification of PET/CT. It excels at detecting skeletal metastases and characterizing benign versus malignant lesions, with faster imaging (uptake ~30–60 min) than a conventional bone scan.
Mechanism
The fluoride ion exchanges for hydroxyl groups in hydroxyapatite, with uptake proportional to bone turnover and regional perfusion — and a higher first-pass extraction than diphosphonates. Like all bone-turnover agents, it images the osteoblastic reaction, not tumor cells directly.
Biodistribution
Skeleton (target), with rapid renal clearance (kidneys/bladder). Low soft-tissue background gives high bone-to-background contrast — a key advantage over Tc-99m agents.
NaF PET vs Tc-99m-MDP Bone Scan
| F-18-NaF PET/CT | Tc-99m-MDP bone scan | |
|---|---|---|
| Modality | PET (± CT) | Planar/SPECT |
| Resolution/sensitivity | Higher | Lower |
| Uptake/imaging time | ~30–60 min | ~2–4 h |
| Localization | Inherent CT | SPECT/CT optional |
| Availability/cost | Cyclotron/PET, costlier | Widely available |
Clinical Indications
- Detection and extent of skeletal metastases (higher sensitivity than planar/SPECT bone scan).
- Characterization of equivocal benign vs malignant lesions with PET/CT correlation.
- Back pain and benign bone conditions where high resolution helps.
Interpretation Highlights
- Metastases: focal, often multiple/axial uptake — but CT correlation is essential (degenerative/traumatic uptake is also intense).
- Purely lytic disease can still be under-represented (uptake reflects bone reaction).
- Quantitative SUV can support serial assessment (protocol-matched).
Reporting Checklist
- Lesion distribution and CT correlation (benign vs malignant morphology).
- Note the bone-reaction caveat (degenerative/traumatic intensity; lytic under-representation).
- State availability/cost context if comparing to a conventional bone scan.
Common Pitfalls
- Degenerative and traumatic uptake are also intense — CT correlation is essential to avoid over-calling metastasis.
- Like all bone-turnover agents, it images the osteoblastic response, not tumor cells directly (lytic under-representation).
- Comparing SUV across mismatched protocols.
Board Pearls
F-18-NaF is a PET bone-seeking agent that exchanges into hydroxyapatite at sites of bone turnover — the same physiology as Tc-99m-diphosphonates but with PET's resolution, sensitivity, and quantification, faster imaging (~30–60 min), and inherent CT localization. It is more sensitive than planar/SPECT bone scintigraphy for skeletal metastases.
NaF images the bone reaction, not tumor cells — so degenerative and traumatic uptake are also intense, and CT correlation is essential to avoid over-calling metastasis; purely lytic disease can still be under-represented.
Availability and cost, not performance, are the usual reasons a conventional bone scan is chosen instead. NaF's low soft-tissue background and rapid renal clearance give high bone-to-background contrast, and higher first-pass extraction than diphosphonates contributes to its sensitivity — but the interpretive caveats of a turnover agent (bone-reaction signal) still apply.
Related Pages
- Related: Bone scintigraphy, tracer MDP/HDP (the Tc-99m equivalent).
- Pitfalls: Pearls, pitfalls & normal variants.
Figure / Diagram Suggestions
- A NaF vs MDP capability comparison (resolution, timing, localization).
- A fluoride–hydroxyapatite exchange mechanism cartoon.
- A metastasis vs degenerative NaF PET/CT teaching pair emphasizing CT correlation.
Self-Check (Board-Style)
Q1. How does NaF PET compare with a Tc-99m-MDP bone scan in sensitivity and speed?
Answer: NaF PET/CT is more sensitive with faster imaging (~30–60 min vs 2–4 h) and inherent CT localization — availability/cost are the usual reasons MDP is chosen instead.
Q2. Does NaF image tumor cells? Why does this matter for interpretation?
Answer: No — it images the osteoblastic bone reaction, so degenerative/traumatic uptake is also intense (CT correlation needed) and purely lytic disease can be under-represented.
Q3. What gives NaF its high bone-to-background contrast?
Answer: Low soft-tissue background with rapid renal clearance and high first-pass bone extraction.
Q4. An intensely avid focus corresponds to an osteophyte on CT. Metastasis?
Answer: No — degenerative uptake is intense on NaF; the CT morphology (osteophyte) identifies it as benign. Always correlate with CT.
Evidence & sources
https://nuc.med/naf-bone-pet/ Report an issue